Referências bibliográﬁ cas: 1. Diário Oﬁ cial da União, 28/07/2008, RE2.605, de julho de 2008. 2. Bula do produto. 3. Tourian KA et al. Efﬁ cacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder. Poster NR6-071
presented at the American Psychiatric Association, May 16-21, 2009, San Francisco, California. 4. Thase ME et al. An Integrated Analysis of the Efﬁ cacy of Desvenlafaxine Compared with Placebo in Patients with Major Depressive Disorder. CNS Spectr
2009;14(3):144-54. 5. Pitrosky B, Thase ME et al. Efﬁ cacy of desvenlafaxine compared with placebo in patients with major depressive disorder: a pooled analysis. Poster presented at the 50th Anniversary of the CINP Congress, 13-17 July 2008, Munich,
Germany. 6. Guico-Pabia C et al. Desvenlafaxine 50 mg/d Improves Functioning and Quality-of-Life Measures in Patients With Major Depressive Disorder. Poster NR6-042 presented at the American Psychiatric Association, May 16-21, 2009, San Francisco, Cali-
fornia. 7. Soares CN, Thase ME, Kornstein SG et al. The efﬁ cacy of desvenlafaxine for improving functioning and quality of life measures in patients with MDD. Poster presented at the 21st ECNP Congress, 30August – 3 September 2008, Barcelona, Spain.